Publications by authors named "Brooks-Rooney C"
Background & Aims: Hepatocellular carcinoma (HCC) risk persists in patients with chronic hepatitis B (CHB) despite antiviral therapy. The relationship between pre-treatment baseline hepatitis B virus (HBV) viral load and HCC risk during antiviral treatment remains uncertain.
Methods: This multinational cohort study aimed to investigate the association between baseline HBV viral load and on-treatment HCC risk in 20,826 noncirrhotic, hepatitis B e antigen (HBeAg)-positive and HBeAg-negative patients with baseline HBV DNA levels ≥2000 IU/mL (3.
Article Synopsis
- A study aimed to validate the link between baseline HBV viral load and the risk of developing hepatocellular carcinoma (HCC) in adults with chronic hepatitis B and without cirrhosis.
- The analysis involved 7,545 patients from Korea, Hong Kong, and Taiwan, and showed that 2.6% (200 patients) developed HCC during an average of 4.28 years of antiviral treatment.
- The findings indicated that higher baseline HBV viral loads (≥8.00 log 10 IU/mL) were associated with the lowest risk of HCC, while lower viral loads increased the risk significantly.
Background & Aims: The comparative risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) receiving tenofovir disoproxil fumarate (TDF) vs. entecavir (ETV) remains controversial. In this individual patient data (IPD) meta-analysis, we aimed to compare HCC risk between the two drugs and identify subgroups who may benefit more from one treatment than the other.
View Article and Find Full Text PDFArticle Synopsis
- The study highlights that chronic hepatitis B (CHB) patients in Japan are aging, with a significant rise in those aged 65 and older from 45.6% to 60.7% between 2012 and 2016.
- The prevalence of nonliver-related health issues, such as cancer, osteoporosis, and renal impairment, has increased, while cirrhosis rates remained stable and hepatocellular carcinoma rates decreased.
- Healthcare costs for these patients have risen dramatically, with median expenses climbing by 119.3%, indicating a growing financial burden on the healthcare system.
Background/purpose: While direct-acting antiviral regimens have been approved for chronic hepatitis C (CHC) patients in Taiwan, reimbursement is limited to certain populations. Thus, pegylated interferon plus ribavirin (PEG-IFN/RBV) remains the standard of care for many patients. The aim of this study was to investigate the percentage of CHC patients who were recommended and willing to receive PEG-IFN/RBV, and to identify reasons why patients were not recommended or unwilling to receive treatment.
View Article and Find Full Text PDFBackground: While direct-acting antivirals have been approved for treating hepatitis C, the guidelines highlight the importance of considering potential drug-drug interactions between DAAs and concomitant medications.
Aim: To assess comorbidity prevalence, concomitant medication use and potential drug-drug interactions between DAAs and concomitant medications for hepatitis C patients in Taiwan.
Methods: This cross-sectional study enrolled 822 patients from May to August 2016 in Taiwan.
Between 80 and 115 million people worldwide are chronically infected with hepatitis C virus, with 60%-90% of these being undiagnosed. Untreated chronic hepatitis C (CHC) is associated with progressive liver disease, cirrhosis, hepatocellular carcinoma and liver-related mortality. A number of extrahepatic manifestations are also reported in CHC patients, further adding to the burden of the disease.
View Article and Find Full Text PDF